Calendario›LKFT›GLPG0492
GLPG0492
GLPG0492 Pharmacodynamics
Ensayo de Lakefront Biotherapeutics NV en Voluntarios sanos.
- Fase
- Fase 1
- Estado
- Completado
- Participantes
- 26
- Centros
- 1
- Fin del objetivo primario
- mar 2012
previstos
fecha real
Qué significa cada fase y cada estado.
Estudio de intervención, aleatorizado, cuádruple ciego. Comenzó en ene 2012.
Qué mide
To evaluate the safety and tolerability of GLPG0492 in terms of adverse events, vital signs, ECG and abnormal lab tests in comparison with placebo (Up to 7 to 10 days after last treatment) (del registro, en inglés)
Cómo lo describe el promotor
En el documentoEn inglés, del registroGLPG0492 is a selective androgen receptor modulator: the compound should help protect against (or help restore) muscle loss in case of immobilization (e.g. after orthopedic surgery) or due to aging (androgenic effect), but without anabolic effects (e.g. effect on testosterone). In the first part of the current study it will be tested whether GLPG0492 given orally to healthy male volunteers increases the protein synthesis in muscle, as measured by the uptake into the muscle of intravenously infused phenylalanine. In the second part of the study, the effect of the compound on the "hormone household" in healthy, postmenopausal women will be assessed.
Más ensayos de LKFT
| Ensayo | Fase | Estado | Lectura de resultados |
|---|---|---|---|
| OM336 | Fase 1 | Reclutando pacientes | dic 2026 (prevista) |
| OM336 | Fase 1 | Reclutando pacientes | jun 2027 (prevista) |
| Long-Term Follow-Up Study of Gamgertamig | no aplica | Aún sin reclutar | dic 2029 (prevista) |
| GLPG CAR T-cell therapy · Hesperia | Fase 3 | Reclutando pacientes | jul 2039 (prevista) |
| GLPG5101 · Atalanta-1 | Fase 1/2 | Interrumpido | may 2026 (real) |
| GLPG3667 · GALARISSO | Fase 2 | Completado | oct 2025 (real) |
Todos los de LKFT, en su ficha.
Ficha completa en ClinicalTrials.gov (NCT01538420), actualizada en abr 2012.